Trends & Analysis

Microbiome-based evidence is set to drive understanding of how drugs interact with human ‘host’ environments, helping devise more targeted treatments and create business opportunities, reports Anthony Finbow, CEO of Eagle Genomics. The microbiology of the drug recipient impacts their immune response, allergic responses and more. Increasingly, life sciences R&D is taking into account the human […]

The Jefferies Healthcare Temperature Check report is now in its third edition and published to coincide with the 11th annual Global Healthcare Conference which was held virtually. Over 500 responses from senior leaders in the sector responded for this year’s report, giving views on both the current state of the market and predictions for 2021. […]

Several pharmacological treatments for non-alcoholic steatohepatitis (NASH) are expected to be launched in the seven major markets (7MM*) over the next 10 years. It is anticipated that these products can demand higher prices than the current off-label therapies, considering no therapy has been approved for the indication, and drive strong growth in the NASH market, […]

R&D spending in the UK pharmaceutical sector has jumped 6.9% annually to an eight-year high, analysis of the latest ONS data by R&D tax relief specialist Catax shows. Total pharmaceutical industry spending on R&D rose to £4.8bn last year, an increase of £306m from the £4.5bn recorded a year earlier1. It was the largest real-terms […]

Lu Rahman looks at the drug repurposing market. How attractive a proposition is it financially?  More than ever the world is watching drug development and is aware of the time it takes to get a drug to market. The 10-15 years that this can involve is costly, so unsurprisingly, drug repurposing has become a credible […]

With COVID-19 taking centre stage in global drug discovery, Lu Rahman looks at opportunities ahead for the sector and where attention might be focussed going forward.  It is clear from the current pandemic that opportunities arise within drug discovery and development when we don’t always expect them. COVID-19 has created an immense global effort centred […]

As the world is rocked by one of the greatest healthcare challenges in living memory, how we treat infectious diseases is becoming one of the key medical questions of our age. Hannah Randles, Health and Life Sciences Champion at Liverpool City Region’s Growth Platform explains how the region’s infectious diseases ecosystem is driving innovation in […]

CRO opens new Oxford site in response to urgent demand from small and medium innovators for specialist scientific expertise. Europital – the global provider of medical management services for clinical research and drug development –is opening a UK site to further expand its services to the UK biotech industry. The company is already working with […]

Alnylam Pharmaceuticals has new data from the open-label extension (OLE) period of the ENVISION Phase 3 study This shows the long-term therapeutic benefit of givosiran in patients with acute hepatic porphyria (AHP)—an orphan disease that can be life threatening. The results were presented by study investigator Eliane Sardh, MD, during a webinar hosted by Alnylam. […]

Continuing to challenge the current HIV treatment paradigm, data presented will investigate new and innovative treatment options for people living with HIV. ViiV Healthcare will be presenting over 20 abstracts during next week at the 23rd International AIDS Conference (AIDS 2020: Virtual), being held 6-10 July. Because of the COVID-19 pandemic, the conference will be […]